Labiotech.eu

News and Trends 14 Nov 2022

InfanDx tackles early detection of hypoxic ischemic encephalopathy

InfanDx AG, a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, has completed the validation of metabolic biomarker panels for the early detection of hypoxic ischemic encephalopathy (HIE) in newborns. The validated biomarkers of such panels will be the target of the company’s HypoxE blood test for […]

November 14, 2022 - 8 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

RSV cases are rising fast in children. Early detection can help.

By Shawn Gaskell, MilliporeSigma RSV-related hospitalizations for 2022 have already surged to unusually high numbers, surpassing cumulative cases typically reported in late December each year, and we’re not even one month into the season. While no age group is immune to RSV— respiratory syncytial virus— and the trouble it can cause, young children are being […]

November 14, 2022 - 5 minutesmins - By External Contributor

Interview 14 Nov 2022

In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus

AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the European Union (EU) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. Beyfortus is the first and only single-dose RSV passive immunization for the broad infant population, including those born healthy, at term […]

November 14, 2022 - 9 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

Early diagnosis tool for childhood kidney disease

Early diagnosis of chronic kidney disease (CKD) is key to managing progression of the disease. A new technique analyzing urine extracellular vesicles (uEVs) — cell-derived nanoscale spherical structures involved in multiple biological functions — in urine samples, identifies changes in the kidneys earlier than conventional methods and can also predict renal function decline. A team […]

November 14, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

A biotech boom manifesting real results in rare pediatric diseases

By Bob Coughlin, managing director, life sciences, JLL For the last two years, the pandemic has resulted in the explosive growth in life sciences. The world watched in awe and anticipation as biotech successfully raced to develop vaccines, therapeutics and diagnostics for Covid-19. It has been a good moment for an industry that deserves such […]

November 14, 2022 - 5 minutesmins - By External Contributor

News and Trends 14 Nov 2022

Researchers discover protein facilitates relapse of pediatric brain tumors

The malignant brain tumor type medulloblastoma can become resistant to therapy, which can cause relapse. Researchers at Uppsala University in Sweden have discovered a protein that makes tumor cells insensitive to radiation treatment. The scientists hope the results could lead to better treatments for children with the highest risk to develop relapses. Avoiding treatment Medulloblastoma […]

November 14, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 11 Nov 2022

Prurigo nodularis treatment recommended for EU approval

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent (dupilumab) in the European Union (EU) to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Dupilumab is being jointly developed by Sanofi and Regeneron. The European Commission is expected […]

November 11, 2022 - 3 minutesmins - By Jim Cornall

CRISPR, CRISPR-Cas9, genome-editing, gene therapy

News and Trends 11 Nov 2022

PACT Pharma reports data from CRISPR cancer study

PACT Pharma, Inc. has reported data from the first clinical study using CRISPR gene editing technology to substitute a gene in patients’ immune cells to treat cancer. Results from the study, which was conducted with collaborators at nine academic centers using PACT Pharma’s platforms, demonstrated early proof-of-concept that a patient’s immune system can be reprogrammed […]

November 11, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 11 Nov 2022

Program management support: accelerating growth for early stage biotechs

More academic groups, new start-ups, biotechs and small pharma companies are turning to external consultants for professional program management support and guidance to help them progress their ideas into medicines for patients. Ian Hollingsworth, associate director of product development at Boyds, a global drug development consultancy, explains the common reasons why academic spinouts and small […]

November 11, 2022 - 6 minutesmins - By External Contributor

News and Trends 11 Nov 2022

Beyond Biotech podcast 22: PacBio, Sierra Space

This week, we have two longer interviews. We have conversations with Neil Ward, VP of PacBio EMEA, and Marc Giulianotti, senior manager in space biomanufacturing at Sierra Space. We also have our weekly contribution from global commercial real estate services company JLL, with Travis McCready. Sierra Space and UC San Diego to develop first stem […]

November 11, 2022

News and Trends 10 Nov 2022

SOTIO reveal potential treatment for adults with solid tumors at SITC meeting

SOTIO Biotech has presented preclinical results of its BOXR T cell therapy platform and revealed it indicates a strong clinical path for its first transgene-expressing CAR-T cell as a potential treatment for solid tumors in adults with cancer. The results were presented at the Society for Immunotherapy of Cancer’s (SITC) 37th annual meeting taking place […]

November 10, 2022 - 4 minutesmins - By Liza Laws

News and Trends 10 Nov 2022

Parthenon and ImaginAb enter into license and supply agreement for anti-cancer therapies

Precision oncology company, Parthenon Therapeutics, and ImaginAb Inc., a global biotech have entered into a multi-year, non-exclusive license and supply agreement. Under the agreement terms, Parthenon will use ImaginAb’s CD8 ImmunoPET imaging technology in its phase 1 trial evaluating its lead compound, PRTH-101, which is expected to begin in 2023. ImaginAb is developing 89Zr crefmirlimab […]

November 10, 2022 - 4 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

InfanDx tackles early detection of hypoxic ischemic encephalopathy

RSV cases are rising fast in children. Early detection can help.

In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus

Early diagnosis tool for childhood kidney disease

A biotech boom manifesting real results in rare pediatric diseases

Researchers discover protein facilitates relapse of pediatric brain tumors

Prurigo nodularis treatment recommended for EU approval

PACT Pharma reports data from CRISPR cancer study

Program management support: accelerating growth for early stage biotechs

Beyond Biotech podcast 22: PacBio, Sierra Space

SOTIO reveal potential treatment for adults with solid tumors at SITC meeting

Parthenon and ImaginAb enter into license and supply agreement for anti-cancer therapies

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!